Skip to main content

Table 2 Bacteriological Examinations

From: Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study

Characteristic

Patients

All

LC

CRC

Other

(n = 30)

(n = 15)

(n = 10)

(n = 5)

Sputum smear, n (%)

 Negative

10 (33.3)

5 (33.3)

3 (30.0)

2 (40.0)

 Positive

20 (66.7)

10 (66.7)

7 (70.0)

3 (60.0)

PCR/LAMP, n (%)

 Negative

1 (3.3)

1 (6.7)

0 (0.0)

0 (0.0)

 Positive

15 (50.0)

10 (66.7)

3 (30.0)

2 (40.0)

 Unknown

14 (46.7)

4 (26.7)

7 (70.0)

3 (60.0)

Culture, n (%)

 Negative

5 (16.7)

3 (20.0)

2 (20.0)

0 (0.0)

 Positive

25 (83.3)

12 (80.0)

8 (80.0)

5 (100.0)

Sensitivity to anti-MTB agents, n (%)

 Sensitive

22 (88.0)

12 (100.0)

6 (75.0)

4 (80.0)

 Resistant

2 (8.0)a

0 (0.0)

2 (25.0)

0 (0.0)

 Unknown

1 (4.0)b

0 (0.0)

0 (0.0)

1 (20.0)b

Time until the result of Bacteriological Examination come out

 

Overall

Ogawa-Kudoh

MGIT

Time to MTB-positive culture (days), mean ± SD, n

20.9 ± 12.4

(n=23c)

37.6 ± 8.4

(n = 5)

16.2 ± 8.7*

(n = 18)

Time to sensitivity testing (days), mean ± SD, n

12.6 ± 3.5

(n=22d)

  
  1. Abbreviations CRC colorectal cancer, LAMP loop-mediated isothermal amplification, LC lung cancer, MGIT Mycobacteria Growth Inhibitor Tube, MTB = Mycobacterium tuberculosis, PCR polymerase chain reaction, NTM Nontuberculous Mycobacteriosis
  2. *P < 0.0005
  3. aOne MTB strain was resistant to isoniazid and streptomycin, another was isoniazid and pyrazinamide
  4. bOne specimen with MTB-positive cultures and concomitant NTM was not used for sensitivity testing
  5. cIn two specimens, measure of the time to MTB-positive cultures were not possible because the culture specimens were obtained in other institutes
  6. dTwenty-two cultures except one which was concomitant NTM and two which was obtained in other institute